LEWYKROPPSDEMENS OCH PARKINSON DEMENS

Per Svenningsson

Neurologiska kliniken, Karolinska Universitetssjukhuset

Översikt

- Lewykroppsdemens: Diagnos och frekvens
- Kognitiv svikt och demens vid Parkinsons sjukdom: Förlopp och frekvens
- Behandling av Lewykroppsdemens och Parkinson demens

Lewy kroppar

Aggregering av felvecklat α-synuclein protein



Lewy kroppar



Spillantini et al Nature. 1997;388:839-40.

Relation mellan Lewykroppsdemens och Parkinson demens



Halliday & McCann 2009

Lewykroppsdemens: Klinska och patologiska kriterier

- Demens
  - → Exekutiv/visuo-spatial
- Kärnsymtom
  - → Kognitiva svängningar
  - → Syn hallucinationer
  - → Parkinsonism
- Vanliga kännetecken
  - → Kärnsymtom inom 1 år
  - → REM sömn beteende störning
  - → Allvarlig, tidig autonom dysfuktion
  - → Depression
  - → Neuroleptika hyperkänslighet
  - → Bevarad medial temporär lob
  - → Positiv DaTSCAN

Lewykroppspatologi

McKeith et al. 2005

Biomarker fynd vid Lewykroppsdemens



Burton et al Brain 2009



McKeith et al Lancet Neurol 2007

Ryggmärgsvätska vid LBD: Sänkt Ab42 och α-syn, normalt tau

Fördelning av Demenssjukdomar inkl Lewykroppsdemens och Parkinson demens



Aarsland et al. Dem Geriatr Cogn Disord 2008

Tid till demensboende vid Alzheimers sjukdom och Lewykroppsdemens



Rongve et al. 2014

Kognitiv svikt och demens vid Parkinsons sjukdom



Kehagia et al Lancet Neurol. 2010



Hely et al. 2008

Farmakologisk behandling av Lewykroppsdemens och Parkinson demens

Kolinesteras hämmare är godkända för behandling av Lewykroppsdemens och Parkinson demens



Wang et al JNNP 2015

Läkemedelsprövningar vid Parkinson demens

Clinicaltrials.gov/EudraCT identifier	Study Design	Estimated enrolment	Agent	Mechanism of action	Comparison
NCT02415062*	Open-label, prospective, randomized paralleled study	150	Donepezil	ChI	Donepezil 25 mg (high dose) vs. Donepezil 10 mg (standard dose)
NCT03413384	Randomized, Double Blinded, Placebo-controlled Phase II Study	106	Ceftriaxone	Cephalosporin antibiotic	Ceftriaxone vs. Placebo
2017-004335-36	Randomized, Double Blinded, Placebo-controlled Phase II Study	120	ANAVEX2-73	Sigma-1 receptor agonist	ANAVEX2-73 vs. Placebo
NCT01738191	Randomised, double-blind, placebo-controlled trial	30	Atomoxetine	Norepinephrine reuptake inhibitor	Atomoxetine vs. Placebo
NCT02258152	Randomised, double-blind, placebo-controlled proof-of-concept trial	82	SYN120	Dual 5-HT6/5-HT2A antagonist	SYN120 vs. Placebo
NCT02871427	Multi-center, open-label, long-term study	80	Nelotanserin	Selective 5-HT2A inverse agonist	Nelotanserin 20, 40, 60 or 80 mg
NCT02910102	Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study	38	Intepiridine	Selective 5-HT6 receptor antagonist	Intepiridin vs. Placebo
NCT03305809	Randomized, Double Blind, Placebo-controlled Phase II Study	340	LY3154207	Dopamine receptor D1 enhancer	LY3154207 vs. Placebo
NCT02562768	Randomized, Double Blind, Placebo-controlled, multiple-ascending dose study	80	LY3154207	Dopamine receptor D1 enhancer	LY3154207 vs. Placebo
NCT01256905*	Open-label	20	Armodafinil	Dopamine reuptake inhibitor	Armodafinil
2017-001673-17	Randomized, double-blind, placebo-controlled, multi-center phase IIa study	40	IRL752	Alpha receptor antagonist	IRL752 vs. Placebo
2010-024424-26	Prospective, multi-center, randomized, double-blind, placebo-controlled, parallel group, phase 2 study	45	Masitinib	Non-selective tyrosine-kinase receptor inhibitor	Masitinib vs. Placebo
NCT02954978	Randomized, Double Blind, Placebo-controlled Study	75	Nilotinib	C-Abelson tyrosine kinase inhibitor	Nilotinib 300 mg vs. Nilotinib 150 mg vs. Placebo
NCT02914366	Randomized, Double Blind, Placebo-controlled Study	75	Ambroxol	Chaperone, glucocerebrosidase stabiliser	Ambroxol 1050 mg vs Ambroxol 525 mg vs. Placebo
NCT02906020	Multicenter, Randomized, Double-blind, Placebo Controlled Study	243	GZ/SAR402671 (Ibiglustat)	Glucosylceramide synthase inhibitor	GZ/SAR402671 vs. Placebo
NCT03456687	Open-label, phase 1 study	20	Exenatide	GLP-1 receptor agonist	Exenatide

Karolinska Institutet

Integrative Research Laboratories

news.cision.com / IRLAB Therapeutics AB / IRLAB reports promising efficacy d...

IRLAB reports promising efficacy data from Phase IIa-study with IRL752

THU, AUG 30, 2018 08:30 CET

The overall results of the recently completed Phase IIa study indicate that IRL752 – a candidate drug developed for the treatment of Parkinson's disease dementia – improves symptoms associated with executive functions and dementia in Parkinson's disease. Effects on balance and fall tendency – so called axial symptoms – and apathy, were significant in patients treated with IRL752 but not in patients treated with placebo. Further, the study indicated a positive trend in results from cognitive tests, despite the short duration of the study. These symptoms currently lack satisfactory treatment. IRLAB has previously reported that IRL752 was well tolerated by patients in this study, which was the study's primary objective.

Sammanfattning

- Lewykroppsdemens är vanligt, troligen 15-20% av demens
- Svår prognos, karakteristisk klinisk presentation
- Kliniska kriterier och biomarkörer (Datscan) ger diagnos
- Kognitiv funktionsnedsättning är också vanlig vid Parkinsons sjukdom
- Handläggning och behandling:
  - → Information och vägledning
  - → Kolinesterashämmare
- Vid frågor: Kontakta gärna Per Svenningsson via 1177.se

TACK!